articles nature publishing group Warfarin (Coumadin, Marevan, and others) is an ideal drug for testing the paradigm of personalized medicine. It is the most commonly prescribed oral anticoagulant in North America and in many European and Asian countries 1 and is a leading cause of adverse drug reactions. [2] [3] [4] Warfarin has a narrow therapeutic index and large interindividual variability in dose requirements, with some individuals requiring <1 mg/day and others >20 mg/day to maintain therapeutic international normalized ratio (INR) values. 5 Tailoring of therapy on the basis of individual INR response often takes weeks, during which the risk of adverse reactions is high. 6, 7 To reduce this risk yet maintain effectiveness, pharmacogenetic algorithms have been developed to estimate the maintenance warfarin dose at the time of warfarin initiation. [8] [9] [10] [11] [12] [13] [14] [15] [16] Besides clinical factors, these initiation algorithms incorporate common single-nucleotide polymorphisms (SNPs)s in the cytochrome P450 (CYP) 2C9 system (CYP2C9*2 and CYP2C9*3) that are associated with impaired metabolism of warfarin 6, [17] [18] [19] and SNPs in the gene for vitamin K epoxide reductase complex 1 (VKORC1) that correlate with warfarin sensitivity. 8, 9, 12, 16, [20] [21] [22] Together, these SNPs explain one-third of the variability in therapeutic dose (R 2 ~33%). 8, 9, 12, 16, [20] [21] [22] Although pharmacogenetic initiation algorithms use these genes and clinical factors to estimate the therapeutic warfarin dose, [8] [9] [10] [11] [12] [13] 16 
explicit guidance for warfarin dosing once the INR response to therapy is known. This limitation is compounded by the common delay of several days in getting genotyping results back from a laboratory. Some experts have argued that even when VKORC1 and CYP2C9 genotypes are available rapidly, this knowledge is neither relevant 23 nor cost-effective. 24 Furthermore, with few exceptions, 8 prior initiation algorithms have been developed in small or single-center studies, and their predictive accuracy in broader populations is questionable. Although the US Food and Drug Administration has included consideration of VKORC1 and CYP2C9 genotyping in the product label of Coumadin/warfarin, several professional organizations do not endorse routine testing (e.g., the American College of Chest Physicians and the American College of Medical Genetics). [25] [26] [27] One reason for such reluctance may be the lack of data on the ability to use VKORC1 and CYP2C9 genotypes to further refine warfarin dose after INRs become available. The recent development of pharmacogenetic refinement algorithms looks promising, 28, 29 but, as these algorithms are specifically tailored to orthopedic patients, they are not applicable to broad populations. In short, it remains unclear whether genotype can help to refine an individual's maintenance dose after several days of warfarin therapy. 23, 30 Therefore, the International Warfarin Dose Refinement Collaboration had two goals: (i) to develop and validate a pharmacogenetic refinement algorithm in an international cohort of patients receiving warfarin for varying indications and (ii) to determine whether genotype is predictive of therapeutic dose even after an INR value becomes available on day 4 or 5 of therapy.
Results Derivation
In the derivation cohort (N = 969), therapeutic dose was inversely correlated with INR, VKORC1-1639 G>A, and the CYP2C9*2 and CYP2C9*3 alleles (P < 0.001). Other significant, independent predictors of therapeutic dose were prior warfarin dose, age, body surface area (BSA), stroke, diabetes, African ancestry, target INR, and use of amiodarone or fluvastatin. Other statins, individually and in combination, were not significant predictors of therapeutic dose in this dataset. Significant predictors of the therapeutic dose in the clinical refinement algorithm were similar (Tables 1 and 2), except that genotype was not offered into that model, and African ancestry was not statistically significant.
The clinical refinement algorithm explained 48% of the variation in the derivation cohort and had a median absolute dosing error of 7.0 mg/week (1.0 mg/day). The pharmacogenetic refinement algorithm explained 63% of the variation in the derivation cohort and had a median absolute dosing error of 5.5 mg/week (0.78 mg/day).
Internal validation
First, we assessed the performance of the pharmacogenetic refinement algorithm in the 204 patients in the internal validation cohort for whom INR values were available on day 4 of therapy. Here, R 2 was 58%, which was significantly (P = 0.002) greater than the R 2 of the clinical refinement algorithm (R 2 = 43%, Table 3 ). The median absolute error (MAE) of the pharmacogenetic refinement algorithm (4.9 mg/week) was less than that of the clinical refinement algorithm (6.1 mg/week) (P = 0.020).
When evaluating algorithms in the smaller internal validation set of patients who had their INR measured on day 5 (N = 105), the results were similar. In this subset, R 2 for the pharmacogenetic algorithm was 60%, which was significantly (P = 0.009) more accurate than the clinical refinement algorithm (R 2 = 44%, Table 3 ). The MAE of the pharmacogenetic refinement algorithm (6.3 mg/week) was less than that of the clinical refinement algorithm (7.4 mg/week), but this difference was not significant (P = 0.16).
Final algorithms
After pooling the derivation and internal validation cohorts (N = 1,213) and rederiving a final model using the same methods, we found that the pharmacogenetic refinement algorithm was: maintenance dose (mg/week) = EXP 
external validation
Evaluation of the final algorithms in external patients who had an INR measured on day 4 (N = 517) yielded an R 2 that was 40% for the final pharmacogenetic refinement algorithm and 28% for the final clinical refinement algorithm. The MAE for both algorithms (6.9 mg/week) was ~1 mg/day. When evaluating algorithms in external patients who had an INR measured on day 5 of therapy (N = 438), the R 2 was 42% for the final pharmacogenetic algorithm and 26% for the final clinical refinement algorithm. Again, the MAEs of the final pharmacogenetic refinement algorithm (6.7 mg/week) and the final clinical refinement algorithm (6.4 mg/week) were both <1 mg/day.
To account for the transient increase in the INR after valve replacement, we calculated a correction factor using the final pharmacogenetic or clinical algorithm of ~1.21 (i.e., the new predicted dose was 21% greater than predicted by the algorithm).
DIscussIon
The public is eager to see a return on its enormous investment in the Human Genome Project. The first payoffs are anticipated in the area of pharmacogenetics, where warfarin has been called the poster child. 31 Warfarin is a classic test case because it has articles a narrow therapeutic index, is influenced by well-characterized genetic factors, and frequently causes adverse events. Now that pharmacogenetic dosing of warfarin is commercially available and several genotyping platforms have been approved by the US Food and Drug Administration, a logistical barrier has become apparent: most medical centers do not have facilities for same-day results that can provide VKORC1 and CYP2C9 genotyping. Even in centers that do have access to genotype Several additional observations warrant discussion. First, VKORC1 was a more important predictor of therapeutic dose in this study than in our prior study of 92 patients with orthopedic conditions. Previously, we found that VKORC1 contributed modestly to dose variability once the INR after three doses was known. 28 However, all the orthopedic patients had received pharmacogenetic therapy prospectively, and therefore the initial warfarin doses already reflected VKORC1 genotype. Second, the effect of incorporating VKORC1 into the new clinical model causes the contribution of INR to R 2 to decrease from 22.2% to 12.3% in the pharmacogenetic one. Consequently, the pharmacogenetic model would be expected to be more robust to errors in initial INR measurements. This robustness may be helpful in patients receiving therapeutic doses of unfractionated or lowmolecular-weight heparin, anticoagulants that sometimes inflate initial INR values. 32 Although much of the variance can be explained by INR, prior doses, age, and (in the pharmacogenetic model) genotype, other variables also affect dose. The lower warfarin requirements in patients who have had a stroke is a new finding and may reflect undernutrition, which is common after a stroke. 33 Our observation that diabetes is a marker for lower warfarin requirements is consistent with prior literature. 34 Several limitations also need to be discussed. As with any international collaboration, we are limited in the number of variables universally available for analysis. For example, some medications (e.g., fluconazole, rifampin, and barbiturates) interact with warfarin, 35 but such interactions occurred too rarely to warrant incorporation into the model, and clinicians will need to account for them (the outliers in Figures 1and 2 demonstrate this necessity). The CYP4F2 V433M genotype was not collected at each site, and incorporation of this genotype might have improved the R 2 . 36 Estimated blood loss was not analyzed here, but this variable can transiently inflate the INR after major surgery. 28, 29 Likewise, the algorithms do not account for decompensated heart failure or patient-specific environmental factors (e.g., dietary vitamin K intake), which may affect warfarin requirements. 37 Finally, although the population of participants of African ancestry is relatively large (N = 123), this analysis is still based on a predominantly Caucasian population.
As a reminder of the importance of considering the limitations of any particular algorithm, we look to the external validation of the final algorithm. Many of these participants (N = 139; 20%) were receiving warfarin for valve replacement. Probably because of destruction and loss of functional clotting factors during cardiopulmonary bypass and because of decreased dietary intake around the time of valve replacement surgery, this population has a transient increased sensitivity to warfarin postoperatively. [38] [39] [40] This indication, however, was rare in the internal data sets, and therefore the algorithms had a tendency to underpredict the therapeutic dosing requirements for these patients, resulting in a lower R 2 and a greater MAE in the external validation cohort.
In contrast to traditional warfarin nomograms, which rely on fixed initial doses and INR response alone, [41] [42] [43] [44] the refinement algorithms developed here accommodate demographics, warfarin indication, concurrent medications, flexible prior warfarin doses, comorbidities, and genotype. The pharmacogenetic refinement algorithm had a greater R 2 and lower dosing error than previous pharmacogenetic algorithms, [8] [9] [10] [11] [12] [13] [14] [15] [16] with the exception of those tailored to specific, homogeneous populations. 28, 29 Whether the high accuracy of the new genetics-based dosing algorithms will improve INR control or clinical outcomes is unknown, but the question is being addressed in three multicenter, randomized trials in the United States (the Clarification of Optimal Anticoagulation through Genetics trial (COAG), the Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis, and the Clinical and Economic Implications of Genetic Testing for Warfarin Management trial) and one in Europe (the European Pharmacogenetics of Anticoagulant Therapy trial (EU-PACT)).
An important advance in personalized medicine will be achieved if the pharmacogenetic algorithm developed here is shown to improve laboratory or clinical outcomes in ongoing trials. Such an achievement would be attributable not to genetic testing per se but rather to a comprehensive approach in which many patient-specific factors are accounted for explicitly. If this approach to warfarin management is any indication of what to expect from the investment in the Human Genome Project, genetics will add to, rather than replace, the list of factors that clinicians need to consider when personalizing therapy. We randomly sampled 80% of the data for derivation, setting aside 20% for internal validation ( Table 4) . Dosing protocols varied among sites, with some participants (31%) being initiated on warfarin therapy using pharmacogenetic dosing algorithms. 28, 29, 45 However, stratifying according to whether sites used a pharmacogenetic dosing protocol did not improve predictive accuracy. After development and internal validation, we studied 584 patients from four additional sites to validate the final algorithm (which was derived by combining the derivation and internal validation cohorts): Vanderbilt University (Nashville, TN; N = 132), the Inje University College of Medicine (Busan, South Korea; N = 139), the University of Utah Hospital (Salt Lake City; N = 117), and the University of Liverpool (UK, N = 196). Data from these 584 additional patients comprised the external validation cohort. Some of the data in this analysis were used for other pharmacogenetic analyses. 8, 9, 16, [28] [29] [30] [46] [47] [48] study outcomes. The outcome variable was the therapeutic (maintenance) warfarin dose, defined as the dose that led to stable therapeutic anticoagulation levels; all sites required therapeutic INR values on at least two consecutive visits. Data from studies that had originally required only a single INR to define therapeutic dose 8, 28, 29 were reanalyzed using the more stringent definition in this analysis.
statistical analysis of the derivation cohort. Using stepwise selection, we quantified the relationship between therapeutic doses and genetic and clinical information available on day 4 or 5 of warfarin therapy ( Tables 1  and 2 ). Variables were allowed to remain in the multivariable linear regression model if they achieved statistical significance (P ≤ 0.05) or were marginally significant (0.05 < P ≤ 0.20) with strong biological plausibility. Because some patients had INR values available on both days 4 and 5 of therapy (N = 355), we used the day 4 INR value for half of the subjects (randomly chosen) in the group and the day 5 value for the other half when deriving the model for each of the 1,000 resamples in the bootstrap procedure. Height and weight data were converted to BSA using the classic formula. 49 We assessed the predictive ability of demographics (gender, race, and African ancestry), warfarin indication (atrial fibrillation, orthopedic surgery, venous thromboembolism, cardiac valve surgery, and stroke), current medications (amiodarone, CYP inducers, and statins), comorbidities (diabetes or liver disease), genotype, and INR values. Categorical variables were coded as 1 if present and 0 if absent. To preserve linearity, we log-transformed the values of the therapeutic doses and of INR. CYP2C9 inducers included rifampin/rifamycin and carbamazepine. Fluvastatin, simvastatin, lovastatin, rosuvastatin, and atorvastatin were tested individually and in combination. Information on other interacting medications was not consistently available from sites. If diabetes status, smoking status, statin use, amiodarone use, or inducer use was not recorded at a particular site (n = 232, n = 148, n = 232, n = 135, and n = 485, respectively), their probabilities were estimated using a likelihood method. Probabilities were then used in the regression equation instead of missing dummy variables. Missing BSA values (n = 38) were imputed from height or weight (if available), sex, or the presence or absence of diabetes.
We coded CYP2C9*2 and CYP2C9*3 SNPs as 0 if absent, 1 if heterozygous, and 2 if homozygous. Likewise, VKORC1-1639 G>A (rs9923231) was coded as 0 (homozygous GG), 1 (heterozygous), or 2 (homozygous AA). If the VKORC1-1639 G>A genotype (also called VKORC1 3673) was missing (N = 241, derivation; N = 57, internal validation), we inferred it from VKORC1 1173/6484 C>T (rs9934438) or VKORC1 1542/6853 G>C (rs8050894), which are in high linkage disequilibrium. 20, 50, 51 To accommodate INRs taken on either day 4 or day 5 of therapy, we defined doses in terms of the number of days they had been administered before the sample was drawn for INR measurement. For example, for patients with an INR available on day 5 of therapy, dose −2 was the dose given 2 days before (on the third day of therapy); dose −3 was the dose given three days before (on the second day of therapy), and so on. In this manner, only one INR (taken on either day 4 or day 5) was required for any individual's dose prediction.
We used 1,000 bootstraps 52 to compare accuracy levels (R 2 and MAE) between the pharmacogenetic and clinical refinement models as well as between the refinement algorithms and previously validated pharmacogenetic and clinical initiation algorithms. 8 Because warfarin use after valve replacement was rare in the derivation and internal validation cohorts (N = 37), we calculated a correction factor for these individuals in a post hoc analysis to quantify the transient warfarin sensitivity after valve replacement (observed previously in refs. [38] [39] [40] ) After external validation, using all data available, we regressed the residual from the final model onto a dummy variable to indicate whether or not a patient (in any cohort) had this indication.
